Hematology Division, Dept. Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Dept. Surgical, Medical, Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
J Biol Regul Homeost Agents. 2020 Sep-Oct;34(5 Suppl. 1):33-38. IORS Special Issue on Orthopedics.
Mesangiogenic Progenitor cells (MPCs) have been isolated from human bone marrow mononuclear cells (hBM-MNCs) and attracted particular attention for their ability to efficiently differentiate into exponentially growing mesenchymal stromal cells (MSCs) and toward endothelial lineage, suggesting the term "mesangiogenic". Coupling mesengenesis and angiogenis, MPCs has been hypothesized retaining a great tissue regenerative potential in musculoskeletal tissues regeneration. Bone marrow and adipose tissue (AT) represent most promising adult multipotent cell sources attempting to repair bone and cartilage, with controversial results regarding advantages applying BM- or AT-derived cells. As different culture determinants as well as tissue of origins, could strongly affect regenerative potential of cell preparations, we hypothesize that MPCs counterpart could have a role in defining efficacy of applying a cell-based medicinal product in musculoskeletal tissue repair. Here we present convincing data demonstrating that the ex vivo progenitors of MPCs are tissue specific and can be detected exclusively in hBM-MNCs.
间充质祖细胞 (MPCs) 已从人骨髓单核细胞 (hBM-MNC) 中分离出来,并因其能够有效分化为指数增长的间充质基质细胞 (MSCs) 和向内皮谱系分化的能力而受到特别关注,这表明了“间充质发生”这一术语。MPCs 结合间充质发生和血管生成,被假设保留了在肌肉骨骼组织再生中强大的组织再生潜力。骨髓和脂肪组织 (AT) 代表最有前途的成人多能细胞来源,试图修复骨骼和软骨,但关于应用 BM 或 AT 衍生细胞的优势存在争议。由于不同的培养决定因素以及组织来源,可能会强烈影响细胞制剂的再生潜力,我们假设 MPCs 的对应物可能在定义细胞药物在肌肉骨骼组织修复中的应用效果方面发挥作用。在这里,我们提出了令人信服的证据,证明 MPCs 的体外祖细胞是组织特异性的,并且只能在 hBM-MNC 中检测到。